CYP3A5 and PPARA genetic variants are associated with low trough concentration to dose ratio of tacrolimus in kidney transplant recipients.
Janaína B F EvertonFernando J B PatrícioManuel S FariaTeresa C A FerreiraElen A RomaoGyl E B SilvaMarcelo MagalhaêsPublished in: European journal of clinical pharmacology (2021)
In the population under study, polymorphisms on CYP3A5 and PPARA were identified as determining and independent factors associated with the reduction of Co/D of TAC. Thus, the genotyping of these genetic variants may be a useful tool for the individualized prescription of TAC in kidney transplant patients.